Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Payables (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Payables for 5 consecutive years, with $7.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 470.81% to $7.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.1 million, a 470.81% increase, with the full-year FY2024 number at $3.0 million, down 62.08% from a year prior.
  • Payables was $7.1 million for Q3 2025 at Werewolf Therapeutics, up from $5.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $13.3 million in Q1 2024 to a low of $986000.0 in Q1 2025.
  • A 5-year average of $3.3 million and a median of $2.0 million in 2021 define the central range for Payables.
  • Peak YoY movement for Payables: surged 555.45% in 2023, then tumbled 92.56% in 2025.
  • Werewolf Therapeutics' Payables stood at $2.0 million in 2021, then crashed by 40.06% to $1.2 million in 2022, then soared by 555.45% to $8.0 million in 2023, then tumbled by 62.08% to $3.0 million in 2024, then soared by 133.21% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Payables are $7.1 million (Q3 2025), $5.2 million (Q2 2025), and $986000.0 (Q1 2025).